Cara Therapeutics
Cara Therapeutics
CARA
NASDAQ
5.25
USD
3.75%
About
Cara Therapeutics, Inc. is a development-stage biopharmaceutical company. The Company is focused on treatment paradigm to improve the lives of patients suffering from chronic pruritus. It is developing an oral formulation of difelikefalin, a selective, predominantly peripherally acting, non-scheduled Kappa opioid receptor agonist, for the treatment of chronic neuropathic pruritus associated with Notalgia Paresthetica (NP), a common, underdiagnosed neuropathy affecting the upper back.
It is conducting Phase II/III Clinical Program in NP. The program is comprised of two studies - KOURAGE 1 and KOURAGE 2, which are double-blind, placebo-controlled, eight-week studies with patients allowed to roll-over into open-label 52-week extensions. It has developed an IV formulation of difelikefalin, for the treatment of moderate-to-severe pruritus associated with advanced chronic kidney disease in adults undergoing hemodialysis.
The IV formulation is out-licensed worldwide..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 359.8K |
| Three Month Average Volume | 18.8M |
| High Low | |
| Fifty-Two Week High | 2.66 USD |
| Fifty-Two Week Low | 0.24 USD |
| Fifty-Two Week High Date | 01 Sep 2023 |
| Fifty-Two Week Low Date | 20 Jun 2024 |
| Price and Volume | |
| Current Price | 0.36 USD |
| Beta | 1 |
| Relative Price Change | |
| Four Week Relative Price Change | -1.51% |
| Thirteen Week Relative Price Change | -48.20% |
| Twenty-Six Week Relative Price Change | -65.54% |
| Fifty-Two Week Relative Price Change | -88.82% |
| Year-to-Date Relative Price Change | -59.08% |
| Price Change | |
| One Day Price Change | 2.42% |
| Thirteen Week Price Change | -44.56% |
| Twenty-Six Week Price Change | -62.11% |
| Five Day Price Change | 3.45% |
| Fifty-Two Week Price Change | -85.99% |
| Year-to-Date Price Change | -51.55% |
| Month-to-Date Price Change | 3.42% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 1.0478 USD |
| Book Value Per Share (Most Recent Quarter) | 0.2115 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 1.0478 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 0.2115 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -1.89396 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.38723 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.20173 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.18864 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.03848 USD |
| Normalized (Last Fiscal Year) | -2.18864 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.18864 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.03848 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.18864 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.03848 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 1.84943 USD |
| Cash Per Share (Most Recent Quarter) | 1.03246 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.18386 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.03313 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.52871 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -145 |
| Cash Flow Revenue (Trailing Twelve Months) | -758 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -1,010.20% |
| Pretax Margin (Last Fiscal Year) | -565.21% |
| Pretax Margin (5 Year) | -162.73% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | 70.56% |
| Gross Margin (Trailing Twelve Months) | 74.66% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -579.43% |
| Operating Margin (Trailing Twelve Months) | -1,000.06% |
| Operating Margin (5 Year) | -167.92% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -565.21% |
| Net Profit Margin (Trailing Twelve Months) | -1,010.20% |
| Net Profit Margin (5 Year) | -162.10% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -20.88% |
| Tangible Book Value (5 Year) | -15.64% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -85.71% |
| Revenue Growth (3 Year) | 9.26% |
| Revenue Change (Trailing Twelve Months) | -59.53% |
| Revenue Per Share Growth | 0.63% |
| Revenue Growth (5 Year) | -46.26% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 100.66% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 37.25% |
| EPS Change (Trailing Twelve Months) | 1.70% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 0 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -56,618,000 |
| Net Debt (Last Fiscal Year) | -100,758,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 1 |
| Price to Sales (Trailing Twelve Months) | 2 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 459 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 35 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 0 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | 4 |
| Quick Ratio (Most Recent Quarter) | 4 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 5 |
| Current Ratio (Most Recent Quarter) | 5 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -94,453,000 |
| Free Cash Flow (Trailing Twelve Months) | -83,326,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -76.94% |
| Return on Assets (Trailing Twelve Months) | -107.38% |
| Return on Assets (5 Year) | -35.76% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -109.80% |
| Return on Equity (Trailing Twelve Months) | -184.32% |
| Return on Equity (5 Year) | -42.56% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -91.50% |
| Return on Investment (Trailing Twelve Months) | -132.61% |
| Return on Investment (5 Year) | -40.82% |